scholarly journals T-Cell Lymphoma in a Patient with Neurofibromatosis Type 1 and AIDS

2017 ◽  
Vol 10 (1) ◽  
pp. 161-168
Author(s):  
Izana Junqueira de Castro ◽  
Esther Botelho Soares da Silva ◽  
Talita Rezende dos Santos ◽  
Amanda Barroso de Freitas ◽  
Inara Junqueira de Castro ◽  
...  
Keyword(s):  
T Cell ◽  
Neurofibromatosis Type 1 ◽  
Cell Lymphoma ◽  
Neurofibromatosis Type ◽  
T Cell Lymphoma ◽  
Malignant Neoplasms ◽  
Non Hodgkin Lymphoma ◽  
Dominant Disease ◽  
Chemotherapeutic Treatment

Neurofibromatosis type 1 (NF1) and AIDS are risk factors for the development of malignant neoplasms, including hematological malignancies, such as non-Hodgkin lymphoma. NF1 is an autosomal dominant disease that primarily manifests as café-au-lait spots, dermal neurofibromas, axillary and/or inguinal ephelides or freckles, plexiform neurofibromas, Lisch nodules, and bone deformities. In this report, we present a 38-year-old female patient with NF1 from childhood and AIDS who developed peripheral T-cell lymphoma with good response to chemotherapeutic treatment.

Primary Cutaneous Follicular Helper T-cell Lymphoma in a Patient With Neurofibromatosis Type 1

2017 ◽  
Vol 39 (2) ◽  
pp. 134-139 ◽  
Author(s):  
Anastasia Shamsuyarova ◽  
Zaid Kamil ◽  
Jan Delabie ◽  
Nadya Al-Faraidy ◽  
Danny Ghazarian
Keyword(s):  
T Cell ◽  
Neurofibromatosis Type 1 ◽  
Cell Lymphoma ◽  
Neurofibromatosis Type ◽  
T Cell Lymphoma ◽  
Helper T Cell ◽  
Follicular Helper ◽  
Follicular Helper T Cell

scholarly journals Primary Pulmonary T-Cell Lymphoma in a Human T-Lymphotropic Virus Type-1 Carrier Showing Atypical Shadow

2010 ◽  
Vol 5 (4) ◽  
pp. 558-559 ◽  
Author(s):  
Shojiro Minomo ◽  
Takayuki Takimoto ◽  
Osamu Morimura ◽  
Akane Watanabe ◽  
Yasuhiro Nagate ◽  
...  
Keyword(s):  
T Cell ◽  
Virus Type ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
T Lymphotropic Virus

scholarly journals EFS12 Is a Powerful Predictive Tool for Outcomes in Stage I Aggressive Non Hodgkin Lymphoma: A Report from Nationwide Registry in a Resource Limited Country Thai Lymphoma Study Group

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 2128-2128
Author(s):  
Kitsada Wudhikarn ◽  
Udomsak Bunworasate ◽  
Jakrawadee Julamanee ◽  
Arnuparp Lekhakula ◽  
Archrob Khuhapinant ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Clinical Characteristics ◽  
Cox Regression ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Stage I ◽  
Non Hodgkin Lymphoma ◽  
Resource Limited ◽  
Lymphoma Study Group

Introduction: Stage I disease represents a minor subset of aggressive Non-Hodgkin Lymphoma (NHL) accounting around 10%. Overall prognosis is generally good but varied upon different histologic subtypes and topographic presentation. Herein, we describe an implication of event free survival at 12 months (EFS12) as a predictor for outcomes of stage I aggressive NHL including real-world data on clinical characteristics and treatment patterns of stage I aggressive NHL in a resource-limited country. Patients and methods: Thai lymphoma study group conducted the lymphoma registry which prospectively enrolled and systematically followed newly diagnosed lymphoma patients between 2007 and 2014 from 13 nationwide major University hospitals. We abstracted data of stage I aggressive NHL patients from the registry and obtained additional information from medical record. Clinical characteristics, treatment patterns and survival outcomes were described. EFS12 was a binary endpoint defined as whether patients developed events at 12 months after treatment initiation. Overall survival (OS) was defined as duration from a specific time-point either at the time of diagnosis, at EFS12 time-point to or at the event to death from any causes. Logistic regression model was used to evaluate the association between clinical characteristics and EFS12. Cox regression with EFS12 as a time-dependent co-variate and other clinical parameters were applied to evaluate association between EFS12 and OS. Results: Of 4,371 newly diagnosed lymphomas, there was a total of 636 stage I lymphoma patients (6.86%) including 590 NHL (519 B cell, 71 T/NK cell) and 46 HL. Among 590 stage 1 NHL, 435 were considered patients (356 diffuse large B cell lymphoma (DLBCL) and 8 Burkitt lymphoma (BL), 19 peripheral T cell lymphoma not otherwise specified (PTCL-NOS), 7 angioimmunoblastic T cell lymphoma (AITL), 11 anaplastic large cell lymphoma (ALCL), 1 other PTCL subtypes and 33 extranodal NK T cell lymphoma (ENKTL)). Table 1 summarizes baseline characteristics and treatment data of stage I aggressive NHL. At the time of analysis 61 patients relapsed and 146 patients had died. Major causes of death included infection related events (n=37, 25.3%), non-infectious related complication (n=21, 14.4%) and disease progression (n=60, 41.1%) respectively. With a median follow up of 47.3 months, both median event free survival (EFS) and overall survival (OS) were not reached with corresponding 4 years EFS and 4 years OS of 79.0% and 68.9% respectively (Figure 1A). Four-years OS of patients with aggressive B cell NHL, PTCL and ENKTL was 70.2%, 75.5% and 48.0% respectively. A total of 328 patients achieved EFS12 (No event within the first 12 months after first line treatment initiation). Patients who achieved EFS12 had significant better OS than patients who failed to achieve EFS12 (4-years OS 89.1% vs 7.1%, Hazard ratio 25.9, 95% Confidence Interval 17.7-37.9, P<0.001) (Figure 1C, 1D). Non-relapsed mortality and cumulative incidence of relapse was 15.1% and 19.0% respectively (Figure 1B). By using multivariable cox regression analysis, factors associated with favorable survival outcomes included absence of B symptoms, complete remission from therapy and achieving EFS12 (Table 2). Conclusion: Stage I disease represented a small proportion of aggressive NHL. Natural history and prognosis were highly varied depending upon histology. EFS12 was a power prognostic factor for stage I aggressive NHL and could be used as a clinical tool to stratify patients. Optimal treatment is to be defined to improve outcome and meanwhile minimize toxicities for stage I aggressive NHL patients. Disclosures No relevant conflicts of interest to declare.

scholarly journals Progressive Heart Failure and Death as the Initial Manifestation of NK/T-Cell Lymphoma: A Case Report and Literature Review

2021 ◽  
Vol 8 ◽  
Author(s):  
Ziyu Zhang ◽  
Shuai Wang ◽  
Qingchun Liang ◽  
Daoquan Peng
Keyword(s):  
Heart Failure ◽  
T Cell ◽  
Cell Lymphoma ◽  
Cytotoxic T Cells ◽  
Late Enhancement ◽  
T Cell Lymphoma ◽  
Rare Type ◽  
Initial Manifestation ◽  
Non Hodgkin Lymphoma ◽  
Nk T Cell

Natural killer/T-cell (NK/T-cell) lymphoma is a rare-type non-Hodgkin lymphoma derived from NK cells or cytotoxic T cells. Here, we present a case of a 40-year-old woman who experienced quick-developed global heart failure and then was diagnosed with NK/T-cell lymphoma through lymphoid biopsy. Neither transthoracic echocardiography nor any radiological images detected a mass in her heart or pericardium. Elevated plasma troponin level and diffused patchy areas of gadolinium late enhancement on cardiac magnetic resonance were compatible with myocarditis. Considering the persistently elevated cytokine level, systemic inflammation symptoms, acute respiratory distress syndrome, and cardiac dysfunction, a cytokine storm secondary to NK/T-cell lymphoma was considered. Due to the refractory malignant arrhythmia, the patient died soon after being admitted to our hospital.

Primary cardiac natural killer/T-cell lymphoma, a very rare form of lymphoma

2018 ◽  
Vol 27 (3) ◽  
pp. 210-212 ◽  
Author(s):  
Frank Farfán-Leal ◽  
Amparo Esteban ◽  
Rocío Hinojar ◽  
Mónica García-Cosío ◽  
Francisco Contreras
Keyword(s):  
T Cell ◽  
Natural Killer ◽  
Cell Lymphoma ◽  
Clinical Manifestations ◽  
T Cell Lymphoma ◽  
Lower Survival Rate ◽  
Natural Killer T Cell ◽  
Non Hodgkin Lymphoma ◽  
Killer T Cell ◽  
Natural Killer T

Extranodal natural killer/T-cell lymphoma is a rare non-Hodgkin lymphoma that is divided into nasal, non-nasal, and aggressive/leukemia subtypes, according to anatomic origin and clinical manifestations, with each subtype carrying a different prognosis. We present a case of primary cardiac natural killer/T-cell lymphoma with extension to other organs in a 38-year-old man, to highlight the role of imaging in categorizing nasal versus non-nasal types. This distinction has relevant implications for patient care because the non-nasal type has a much lower survival rate.

scholarly journals Case of Primary Breast and Ipsilateral Axillary T-Cell Lymphoma: a Rare Occurrence

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Faryal Afridi ◽  
Garry D. Ruben ◽  
Eric Oristian
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
T Cell Lymphomas ◽  
Lost To Follow Up ◽  
Ipsilateral Axilla ◽  
Rare Diagnosis ◽  
Breast Malignancies

Background. Malignant lymphomas of the breast are rare and can be primary or secondary. Non-Hodgkin Lymphoma involving the breast is even rarer comprising 0.04-0.5% of all breast malignancies (Takemura). The incidence is even lower for T-cell lymphomas compared with B-cell subtype. We report the rare incidence of primary T-cell lymphoma involving both breast and ipsilateral axilla. Case. This is the case of an 80-year-old female who initially presented with asymmetry of her right breast. Initial mammograms were inconclusive. MRI could not be performed due to the patient’s severe claustrophobia. The patient was then lost to follow-up but re-presented with a new palpable density in the same breast. Subsequent mammogram showed a suspicious lesion with suspicious right axillary lymphadenopathy. Core biopsy was consistent with T-cell lymphoproliferative disorder involving both the breast and the axilla. She was then referred to medical oncology for management. Conclusion. Although rare, lymphoproliferative disorders of the breast can be encountered during workup for suspicious breast lesions. It is imperative that the surgeon is aware of this rare diagnosis to facilitate appropriate therapeutic intervention.

scholarly journals Seroprevalence of human T-cell lymphoma/leukemia virus type-1 (HTLV-1) antibodies among blood donors at Enugu, Nigeria

2015 ◽  
pp. 31 ◽  
Author(s):  
Robinson Onoh ◽  
Augustine Okoye ◽  
Godswill Obed Ibegbulam ◽  
Ngozi Immaculata Ugwu ◽  
Chukwudi Siemon Anigbo ◽  
...  
Keyword(s):  
T Cell ◽  
Virus Type ◽  
Blood Donors ◽  
Cell Lymphoma ◽  
Leukemia Virus ◽  
T Cell Lymphoma ◽  
Human T Cell

Guttate morphoea in human T-cell lymphoma/lymphotrophic virus type-1 (HTLV-1) infection

2003 ◽  
Vol 28 (4) ◽  
pp. 380-382 ◽  
Author(s):  
N. Oiso ◽  
K. Fukai ◽  
N. Hosomi ◽  
M. Ishii
Keyword(s):  
T Cell ◽  
Virus Type ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Human T Cell
Sign in / Sign up

Export Citation Format

Share Document